STOCK TITAN

Ideaya Biosciences Inc - IDYA STOCK NEWS

Welcome to our dedicated news page for Ideaya Biosciences (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ideaya Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ideaya Biosciences's position in the market.

Rhea-AI Summary
IDEAYA Biosciences, Inc. announces pricing of public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences announces plans for a public offering of up to $125.0 million of its common stock and pre-funded warrants. The offering is subject to market conditions and the underwriters have a 30-day option to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences presents clinical data on darovasertib in metastatic uveal melanoma at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
Rhea-AI Summary
IDEAYA Biosciences announces the publication of abstract for a proffered paper session at ESMO 2023, presenting clinical data from Phase 2 trial of darovasertib in combination with crizotinib in metastatic uveal melanoma (MUM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences initiates Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences selects a Werner Helicase Inhibitor Development Candidate and announces an Investor R&D Day
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
Rhea-AI Summary
IDEAYA Biosciences grants stock options to newly hired employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary
IDEAYA Biosciences receives Fast Track designation from the FDA for IDE161 in breast cancer treatment, expanding its development program. Phase 1 expansion shows preliminary tumor shrinkage in multiple patients with HRD solid tumors. Program updates expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
Rhea-AI Summary
IDEAYA Biosciences initiates Phase 1 expansion of IDE161 in HRD solid tumors, demonstrating preliminary tumor shrinkage and target engagement. Clinical program updates expected in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
Ideaya Biosciences Inc

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

3.13B
73.78M
0.98%
102.9%
12.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About IDYA

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.